| |
| |
|
| Insider
Information: |
Katkin Keith |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
1,275,920 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$4,892,366 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,275,920 |
|
|
| Total
Value |
$4,892,366 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Avanir Pharmaceuticals |
AVNR |
President and CEO, Dir... |
2014-12-17 |
914,249 |
2006-05-25 |
0 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
Director |
2017-05-10 |
12,119 |
|
0 |
Premium* |
|
|
Urovant Sciences Ltd. |
UROV |
PEO;CEO/Urovant Scienc... |
2020-02-19 |
199,680 |
2019-12-09 |
0 |
Premium* |
|
|
Syndax Pharmaceuticals Inc |
SNDX |
|
2024-02-07 |
65,000 |
2021-02-03 |
0 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
Director |
2021-05-19 |
25,000 |
2021-05-19 |
0 |
Premium* |
|
|
Emergent Biosolutions Inc. |
EBS |
Director |
2024-05-23 |
59,872 |
2022-04-02 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
77 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2010-05-03 |
4 |
AS |
$3.06 |
$201,376 |
D/D |
(65,906) |
271,367 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2013-05-15 |
4 |
AS |
$3.26 |
$816,313 |
D/D |
(250,438) |
495,107 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2010-04-30 |
4 |
AS |
$3.31 |
$132,372 |
D/D |
(40,000) |
337,273 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2012-06-25 |
4 |
AS |
$3.50 |
$664,791 |
D/D |
(190,125) |
137,732 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2019-12-09 |
4 |
OE |
$3.86 |
$463,200 |
D/D |
120,000 |
120,000 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
OE |
$3.86 |
$694,800 |
D/D |
180,000 |
379,680 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2010-12-02 |
4 |
S |
$4.08 |
$797,254 |
D/D |
(195,300) |
208,352 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2013-11-01 |
4 |
AS |
$4.14 |
$18,138 |
D/D |
(4,385) |
475,222 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2013-08-02 |
4 |
AS |
$4.84 |
$74,981 |
D/D |
(15,500) |
479,607 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-05-28 |
4 |
AS |
$5.01 |
$2,215,482 |
D/D |
(442,212) |
750,082 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-08-01 |
4 |
AS |
$5.26 |
$50,864 |
D/D |
(9,670) |
760,412 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2010-11-01 |
4 |
AS |
$5.70 |
$114,000 |
D/D |
(20,000) |
145,852 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-09-30 |
4 |
OE |
$7.88 |
$28,740 |
D/D |
3,561 |
32,647 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-03 |
4 |
OE |
$7.88 |
$1,432 |
D/D |
180 |
32,013 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-04 |
4 |
OE |
$7.88 |
$3,071 |
D/D |
360 |
32,223 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-06 |
4 |
OE |
$7.88 |
$245,177 |
D/D |
29,899 |
41,117 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Sr. V.P. of Sales & Marketing |
• – – |
2006-05-25 |
4 |
B |
$8.98 |
$22,484 |
D/D |
2,500 |
2,500 |
2.74 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-10-24 |
4 |
AS |
$11.76 |
$324,188 |
D/D |
(27,567) |
732,845 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2019-12-09 |
4 |
AS |
$12.78 |
$1,533,600 |
D/D |
(120,000) |
0 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
D |
$13.08 |
$983,773 |
D/D |
(75,212) |
199,680 |
0 |
- |
|
| UROV |
Urovant Sciences Ltd. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2020-02-19 |
4 |
D |
$13.08 |
$1,370,627 |
D/D |
(104,788) |
274,892 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-12-17 |
4 |
AS |
$16.93 |
$1,058,464 |
D/D |
(62,520) |
914,249 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
President and CEO |
• • – |
2014-12-15 |
4 |
AS |
$16.95 |
$3,646,962 |
D/D |
(215,160) |
976,769 |
0 |
- |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-03 |
4 |
AS |
$25.00 |
$4,500 |
D/D |
(180) |
32,000 |
0 |
% |
|
| SNDX |
Syndax Pharmaceuticals In... |
|
– • – |
2022-10-04 |
4 |
AS |
$25.00 |
$9,000 |
D/D |
(360) |
32,000 |
0 |
% |
|
77 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
